Format

Send to

Choose Destination
Expert Rev Cardiovasc Ther. 2015 Jan;13(1):75-83. doi: 10.1586/14779072.2015.988142. Epub 2014 Nov 29.

Stem cells in the management of heart failure: what have we learned from clinical trials?

Author information

1
The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, 1 Discovery Drive, Rensselaer, NY 12144, USA.

Abstract

Research shows that various types of stem cells (SCs) have the ability to rebuild damaged heart tissue. The TIME and Late TIME human trials shed light on the optimum timing of SC therapy administration after myocardial damage. The FOCUS study failed to show a substantial positive effect of bone marrow-derived mononuclear cells in patients suffering from ischemic heart failure; however, some completed human trials do show promise, with improvement in cardiac function. Recent clinical trials have identified a subset of marrow cells that was able to stimulate endogenous adult cardiac SCs where cardiac SCs administration showed promise in the SCIPIO trial. This review addresses some of the lessons learned from clinical trials with SC therapy in ischemic heart failure.

KEYWORDS:

cardiac function; congestive heart failure; hypertension; ischemic heart failure; myocardial infarction; pharmacotherapy; stem cell

PMID:
25434419
DOI:
10.1586/14779072.2015.988142
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center